No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1235.2x · 10Y median 81.4x · 100th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:00:17.322Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Absci Corporation (ABSI) stock was $11.38 as of Oct 6, 2026, 10:00 AM EDT, down 1.28% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +239.1% · 3-year avg +103.4%/yr · 5-year avg +0.9%/yr
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States.
Biotechnology · Vancouver, WA
Next Earnings Date
Nov 16, 2026
41 days away
EPS Estimate
-0.19
Revenue Est.
$697567.00
Last Quarter Results
EPS
$-0.21
vs Estimate
$-0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ABSI | $1.93B | $11.38 | -1.28% | +239.13% | +0.89% | N/A | N/A |
| 2ESTA | $1.96B | $66.76 | +0.43% | +60.08% | -1.56% | N/A | vs ABSI |
| 3BLFS | $1.89B | $38.61 | +3.51% | +44.95% | -0.77% | +36.27% | vs ABSI |
| 4AGIO | $1.87B | $31.32 | +0.22% | -22.74% | -6.59% | -5.39% | vs ABSI |
| 5IMNM | $1.99B | $20.80 | -1.73% | +70.56% | +2.88% | N/A | vs ABSI |
| 6ASTH | $1.85B | $37.27 | +1.25% | +27.88% | -16.52% | +25.17% | vs ABSI |
forward FY estimate
N/A
$300000.00
vs Estimate
$919583.00
Consensus Rating
Based on 10 analysts
Average Price Target
$14.40
+26.5% upside
Low
$10.00
Current
$11.38
High
$17.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.24 | $-0.19 | $-0.14 | 5 |
| Quarter ending Dec 2026 | $-0.22 | $-0.19 | $-0.18 | 5 |
| Quarter ending Mar 2027 | $-0.54 | $-0.15 | $0.01 | 3 |
| Quarter ending Jun 2027 | $-0.59 | $-0.16 | $0.01 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.90 | $-0.80 | $-0.75 | 6 |
| FY 2027 | $-1.09 | $-0.72 | $-0.34 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $122007.00 | $697567.00 | $2.39M | 7 |
| Quarter ending Dec 2026 | $186751.00 | $1.10M | $3.36M | 7 |
| Quarter ending Mar 2027 | $833333.00 | $4.90M | $15.00M | 3 |
| Quarter ending Jun 2027 | $624999.00 | $3.67M | $11.25M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $916648.00 | $3.89M | $11.32M | 8 |
| FY 2027 | $1.03M | $16.00M | $52.08M | 8 |
